Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Instruments Shows NanoSight NTA at BioNanoMed 2014

Published: Saturday, March 01, 2014
Last Updated: Friday, February 28, 2014
Bookmark and Share
BioNanoMed 2014 to be held in Krems, Austria from 26 - 28 March.

Malvern Instruments will demonstrate NanoSight Nanoparticle Tracking Analysis (NTA) at BioNanoMed 2014, the 5th International Congress on Nanotechnology, Medicine and Biology, which takes place in Krems, Austria from 26 - 28 March.

A specialist from the company will also make a 10-minute presentation as part of the business sessions held alongside the conference.

The acquisition of NanoSight in September 2013 has extended Malvern’s range of analytical solutions for characterization at the nanoscale, with NTA ideally complementing the company’s Zetasizer Nano, Archimedes and Viscotek SEC systems.

NanoSight Nanoparticle Tracking Analysis detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on the material, determining concentration and measuring the size of each particle from direct observations of diffusion. It does this with high resolution, in real time and with minimal sample preparation.

Additionally, a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner.

Key conference topics at BioNanoMed 2014 include: Novel Nanomedical Solutions - Advances in Nanomedicine; Nanomaterials for Biomedical Applications; Nano-Oncology: Diagnostic, Drug Delivery and Therapy; and NanoPharmaceuticals.

Themed sessions cover: Nano-Bio-Sensing: New Sensing Approaches, Visions and Perspectives in Diagnosis and Therapy; Nano-Imaging Technologies in Medicine; and NanoSafety: Innovation-Enabler for Nanomedicine.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Time at Pittcon for new Malvern Systems
Malvern is exhibiting its particle characterization and rheology ranges at Pittcon 2006.
Thursday, January 05, 2006
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!